“Global Pulmonary/Respiratory Drug Delivery market set to grow to $62bn by 2024” says new Visiongain report

29 May 2019
Pharma

Visiongain has launched a new pharma report Global Respiratory Drug Delivery Market: Suspension Aerosol, Solution Aerosol, Dry Powder Formulation, Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories, Plain Canister, Coated Canister, Asthma, COPD, Cystic Fibrosis, Other Applications, Hospitals & Clinics, Homecare Settings.

The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.

The lead analyst of the report commented "Technological advances in drug delivery will have a positive impact on the market for pulmonary drug delivery devices. These advances include the electronic dose counter MDI, incorporation of agglomerated vesicle technology, and technology for supercritical fluids. Moreover, increasing demand for advanced drug delivery devices, improving healthcare infrastructure, ease of use, and increase in healthcare spending are some of the major factors that will provide lucrative opportunities in the near future."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva and other companies

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Visiongain Publishes Antibacterial Drugs Market Report 2021-2031

The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.

13 November 2020

Read

Visiongain Publishes Topical Drug Delivery Market Report 2020-2030

Delivery of biologics through the transdermal route is anticipated to open new avenues for the manufacturers of topical drugs. Transdermal route provides appropriate and painless self-administration for patients. It overcomes frequent dosing administration, plasma level instability related to oral dosing and injections to uphold constant drug concentrations, and a drug with a short half-life can be supplied effortlessly.

11 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever